Neogen (NEOG) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.00%. A quarter ago, it was expected that this maker of medical testing kits would post earnings of $0.08 per share when it actually produced earnings of $0.05, delivering a surprise of -37.5%.Over the last four quarters ...

Core Viewpoint - Holley Inc. (HLLY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by an upward trend in earnings estimates, which significantly impacts stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system focuses on changes in earnings estimates as a key determinant of stock ratings, with the consensus estimate for Holley showing a 18.9% increase over the past three months [8][4]. - For the fiscal year ending December 2025, Holley is expected to earn $0.23 per share, which remains unchanged from the previous year [8]. Investment Implications - The upgrade reflects an improvement in Holley's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][3]. - The Zacks Rank system, which categorizes stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank 1 stocks averaging a +25% annual return since 1988 [7][6]. Market Positioning - Holley's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][9].

PureTech Health PLC Sponsored ADR (PRTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.T ...

Group 1 - Medical Properties (MPW) has recently crossed above the 200-day moving average, indicating a potential long-term bullish trend [1] - The stock has rallied 26.7% over the past four weeks, suggesting positive momentum [2] - MPW currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [2] Group 2 - There have been two upward revisions in earnings estimates for the current fiscal year, with no downward revisions, reinforcing a bullish sentiment [3] - The consensus estimate for earnings has also increased, further supporting the positive outlook for MPW [3] - The combination of positive technical indicators and earnings estimate revisions suggests that MPW may experience further gains in the near future [3]

Group 1 - Semtech reported quarterly earnings of $0.41 per share, exceeding the Zacks Consensus Estimate of $0.40 per share, and showing a significant increase from $0.11 per share a year ago, representing an earnings surprise of +2.50% [1] - The company achieved revenues of $257.6 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 0.61% and increasing from $215.35 million year-over-year [2] - Semtech has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has underperformed the market, losing about 17.4% since the beginning of the year, while the S&P 500 has gained 10% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.44 on revenues of $264.8 million, and for the current fiscal year, it is $1.66 on revenues of $1.04 billion [7] Group 3 - The Zacks Industry Rank places the Semiconductor - Analog and Mixed sector in the top 11% of over 250 Zacks industries, indicating strong potential for outperformance compared to lower-ranked industries [8] - The estimate revisions trend for Semtech was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

Hesai Group Sponsored ADR (HSAI) closed the last trading session at $23.26, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $30.15 indicates a 29.6% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $4.76. While the lowest estimate of $23.30 indicates a 0.2% increase from the current price level, the most optimisti ...

Company Performance - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company posted revenues of $0.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 22.32%, and showing a significant increase from zero revenues a year ago [2] - Over the last four quarters, RenovoRx has surpassed consensus EPS estimates two times [1] Stock Performance - RenovoRx shares have declined approximately 5.4% since the beginning of the year, while the S&P 500 has gained 10% [3] - The current Zacks Rank for RenovoRx is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.44 million, and for the current fiscal year, it is -$0.32 on revenues of $1.61 million [7] - The trend of estimate revisions for RenovoRx was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - RenovoRx operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 41% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

分组1 - Adtalem Global Education reported quarterly earnings of $1.66 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, and showing an increase from $1.37 per share a year ago, resulting in an earnings surprise of +9.93% [1] - The company achieved revenues of $457.11 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.97%, and up from $409.91 million year-over-year [2] - Adtalem has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong financial performance [2] 分组2 - The stock has gained approximately 31.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $1.63 for the coming quarter and $7.47 for the current fiscal year [4][7] - The Zacks Industry Rank places the Schools industry in the top 15% of over 250 Zacks industries, suggesting a favorable environment for Adtalem's stock performance [8]

Company Performance - Ambac Financial Group reported a quarterly loss of $0.22 per share, which was better than the Zacks Consensus Estimate of a loss of $0.24, and compared to earnings of $0.18 per share a year ago, indicating an earnings surprise of +8.33% [1] - The company posted revenues of $54.96 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.14%, and down from $105 million in the same quarter last year [2] - Over the last four quarters, Ambac has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during this period [2] Stock Performance - Ambac shares have declined approximately 32.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $59.66 million, and for the current fiscal year, it is -$0.67 on revenues of $249.95 million [7] Industry Outlook - The Insurance - Property and Casualty industry, to which Ambac belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Summary of Key Points Core Viewpoint - RxSight, Inc. reported a quarterly loss of $0.08 per share, which was better than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of +20.00% [1] - The company has shown mixed performance in terms of revenue and earnings estimates over the past year, with a significant decline in stock price [3][4] Financial Performance - For the quarter ended June 2025, RxSight posted revenues of $33.64 million, slightly surpassing the Zacks Consensus Estimate by 0.11%, but down from $34.89 million a year ago [2] - Over the last four quarters, the company has exceeded consensus revenue estimates four times [2] Stock Performance and Outlook - RxSight shares have decreased approximately 78% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $29.04 million, and for the current fiscal year, it is -$0.49 on revenues of $126.63 million [7] Industry Context - The Medical - Instruments industry, to which RxSight belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of RxSight's stock may be influenced by the overall outlook of the industry [8]